Form 4 for KURA Kura Oncology, Inc.
Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-20 · accession 0000950170-24-062585 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-05-20 | 2024-05-20 | KURA | Bair Teresa Brophy | CLO | S - Sale | $22.15 | -2,615 | 69.0K | -4% | -$57.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | S | D | 2,615 | $22.15 | 68,979 | D | — | — | (F2) 2615 shares were acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. (F3) This transaction was executed in multiple trades at prices ranging from $22.06 to $22.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F4) The reported sale of 2,615 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023. |